THERAPY Neuroendocrine cancer-are two radionuclides better than one?

Dik Kwekkeboom

doi:10.1038/nrendo.2012.64

THERAPY Neuroendocrine cancer-are two radionuclides better than one?

Dik Kwekkeboom

Radiology & Nuclear Medicine

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Peptide-receptor radionuclide therapy with radiolabelled somatostatin analogues is a successful new treatment modality for patients with neuroendocrine tumours. Usually, (90)yttrium (Y-90)-coupled or (177)lutetium (Lu-177)-coupled somatostatin analogues are used, but a new study claims that combining the two radiopharmaceuticals results in improved overall survival.

Original language	Undefined/Unknown
Pages (from-to)	326-328
Number of pages	3
Journal	Nature Reviews Endocrinology
Volume	8
Issue number	6
DOIs	https://doi.org/10.1038/nrendo.2012.64
Publication status	Published - 2012

Research programs

EMC MM-01-40-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrendo.2012.64

http://hdl.handle.net/1765/52789

Cite this

@article{46c4af847572454fb76e299d94fa557e,

title = "THERAPY Neuroendocrine cancer-are two radionuclides better than one?",

abstract = "Peptide-receptor radionuclide therapy with radiolabelled somatostatin analogues is a successful new treatment modality for patients with neuroendocrine tumours. Usually, (90)yttrium (Y-90)-coupled or (177)lutetium (Lu-177)-coupled somatostatin analogues are used, but a new study claims that combining the two radiopharmaceuticals results in improved overall survival.",

author = "Dik Kwekkeboom",

year = "2012",

doi = "10.1038/nrendo.2012.64",

language = "Undefined/Unknown",

volume = "8",

pages = "326--328",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",